Loading organizations...
§ Private Profile · South San Francisco, CA, USA
A medical diagnostics company developing microfluidic deformability cytometry technology for rapid sepsis and immune response tests.
CytoVale is a medical diagnostics company that develops microfluidic deformability cytometry technology to analyze the innate immune response for rapid disease detection. The organization primarily serves hospitals and health systems with its flagship product, IntelliSep, a pathogen-agnostic diagnostic test designed to quickly detect and manage sepsis in acute clinical settings. Following regulatory clearance from the FDA in January 2023, the enterprise began generating revenue from commercial healthcare customers and previously adapted its clinical studies to address the global COVID-19 pandemic. To support its ongoing commercialization and manufacturing efforts, the firm raised over $80 million in Series C funding in 2023 and appointed industry executives like Lindy Fishburne to its board of directors. Originating from early academic research conducted in 2007, CytoVale was officially founded in 2013 by Ajay Shah, Henry Tse, and Dino Di Carlo.
CytoVale has raised $191.5M across 4 funding rounds.
CytoVale has raised $191.5M in total across 4 funding rounds.
CytoVale has raised $191.5M across 4 funding rounds. Most recently, it raised $100.0M Series D in October 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2024 | $100M Series D | Sands Capital | Accomplice VC, Alumni Ventures, Aniq Kassam, Matrix, Night Capital, SignalFire, Susa Ventures, Elliott Cohen, Sunil Paul, Travis MAY | Announced |
| Nov 1, 2023 | $84M Series C | Norwest Venture Partners | Alumni Ventures, Entrée Capital Ventures, Insight Partners, Mercury Fund, Norwest Venture Partners, Pitango Venture Capital | Announced |
| Oct 30, 2019 | $7.4M Series B Plus | Blackhorn Ventures, Breakout Ventures | — | Announced |
| May 1, 2018 | $65K Series B | — | Ankona Capital, Ehukai Investments | Announced |
Cytovale is a commercial-stage medical diagnostics company headquartered in South San Francisco, California, specializing in rapid diagnostic technologies for immune-mediated diseases, with a primary focus on early sepsis detection.[1][2][3] Its flagship product, IntelliSep, is an FDA-cleared test that uses microfluidics, machine learning, and biomechanical analysis of white blood cells from a standard blood draw to stratify sepsis risk in 8-10 minutes, serving emergency departments (EDs) to enable faster triage, reduce unnecessary antibiotics and blood cultures, shorten hospital stays, and cut costs.[1][2][3][5] Sepsis, the leading cause of hospital deaths in the U.S. (claiming 270,000 lives annually), remains Cytovale's core target, addressing diagnostic challenges in this fast-moving, dysregulated immune response condition; the company reported $33M in revenue and earned Modern Healthcare's 2024 Best in Business recognition for IntelliSep's clinical and financial impact.[1][3]
Cytovale traces its roots to academic research starting in 2007, officially incorporating in 2013 to commercialize microfluidic deformability cytometry for innate immune response analysis.[1][4] Co-founder and CTO Henry Tse, PhD, a key inventor with expertise in microfluidics, cancer biology, image processing, and clinical studies (BS from UC San Diego, PhD from UCLA), drove the core technology, backed by peer-reviewed publications and patents.[4] Co-founder and CEO Ajay Shah leads the mission to transform sepsis care, emphasizing the condition's deadliness.[3] The idea emerged from unmet needs in rapid sepsis diagnosis; early traction built through FDA clearance for IntelliSep and partnerships with hospitals like St. Francis Medical Center, evolving into a venture-backed firm supported by Norwest Venture Partners, Sands Capital, and Global Health Investment Corporation.[3][4][6]
Cytovale rides the wave of AI-driven precision diagnostics in biotech, targeting immune-mediated diseases amid rising sepsis burdens—exacerbated by aging populations, antimicrobial resistance, and post-pandemic hospital strains.[1][2][3] Timing is critical: sepsis kills more than opioids, prostate/breast cancer combined, costing hospitals billions; IntelliSep fills a gap in early, objective detection at presentation, influencing ED workflows and sepsis protocols nationwide.[2][3][5] Market forces like value-based care, ED overcrowding, and demand for rapid, cost-saving tools favor expansion; as a B2B healthcare innovator, Cytovale shapes the ecosystem by partnering with health systems, publishing data-driven best practices, and paving the way for broader immune profiling applications.[1][3][6]
Cytovale's momentum—fueled by IntelliSep's validation, revenue growth, and awards—positions it for national scaling and pipeline expansion into other immune diseases like infections or autoimmunity.[1][3] Trends in AI-biotech convergence, regulatory tailwinds for rapid tests, and hospital focus on sepsis bundles will accelerate adoption, potentially amplifying influence through health system networks and new indications.[1][3][5] Watch for deepened integrations, clinical outcome publications, and funding rounds to fuel growth; as sepsis detection evolves from reactive to proactive, Cytovale stands to redefine ED standards, saving lives and echoing its founding promise of immune insight at speed.[3][4][6]
CytoVale has raised $191.5M in total across 4 funding rounds.
CytoVale's investors include Sands Capital, Accomplice VC, Alumni Ventures, Aniq Kassam, Matrix, Night Capital, SignalFire, Susa Ventures, Elliott Cohen, Sunil Paul, Travis May, Norwest Venture Partners.